Pharmaceuticals, Biotechnology and Life Sciences
The Prange Group and its affiliate Adragos Pharma have successfully acquired the Fresenius Kabi production site in Halden, Norway, a leading sterile pharmaceutical manufacturing facility. This strategic move signifies a significant step forward for both companies, expanding their global footprint and enhancing their capacity for sterile liquid production.
New findings from the VESTIGE trial reveal the effectiveness of Dupixent (dupilumab) in managing uncontrolled moderate-to-severe asthma.
Oxford Cannabinoid Technologies Holdings, the biotech company developing prescription cannabinoid medicines, has appointed Lord Mott OBE as an independent Non-Executive Director, effective immediately.
GSK has appointed Dr Jeannie Lee to the Board of the Company as a Non-Executive Director, who will join the Board on 4 March 2024.
PulseSight Therapeutics SAS, a biotech company, launches with funding from Pureos Bioventures and ND Capital. It aims to validate its innovative delivery platform by advancing drugs for age-related macular diseases.
A strategic partnership between Akeada and Biological E. Limited aims to hasten access to QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs) for National Immunization Programs by 2030. MDVs offer cost and logistical benefits, with BE aiming for a manufacturing capacity of 50 million doses yearly to support Takeda’s goal of 100 million doses annually within the decade.
Santhera Pharmaceuticals has revealed that AGAMREE (vamorolone) has received approval in the United Kingdom (UK) for treating Duchenne muscular dystrophy (DMD) in patients aged 4 and above, regardless of the underlying mutation and ambulatory status.
Mainz Biomed N.V., a company focused on molecular genetics diagnostics for early cancer detection, is confirming its collaboration with TestDNA at the forthcoming 10th Gdańsk Gastroenterology Symposium scheduled for January 12th–13th, 2024. The joint effort aims to progress the detection of colorectal cancer (CRC) in Poland, with a focus on introducing innovative approaches that can improve treatment choices and elevate survival rates through early identification of the disease.
Novartis has reported successful outcomes for Scemblix® (asciminib) in its pivotal Phase III ASCFIRST trial, a head-to-head comparison for newly diagnosed patients with Philadelphia chromosome-positive CML (Ph+ CML-CP).
Destiny Pharma, a clinical-stage biotech firm dedicated to developing and marketing innovative medicines to prevent life-threatening infections, has issued a year-end business update, as it focuses on XF-73 nasal and NTCD-M3 programs.